143 related articles for article (PubMed ID: 21849398)
21. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
23. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
24. Defining a radiotherapy target with positron emission tomography.
Black QC; Grills IS; Kestin LL; Wong CY; Wong JW; Martinez AA; Yan D
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1272-82. PubMed ID: 15519800
[TBL] [Abstract][Full Text] [Related]
25. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
[TBL] [Abstract][Full Text] [Related]
26. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
28. Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.
Hatt M; Cheze-Le Rest C; Aboagye EO; Kenny LM; Rosso L; Turkheimer FE; Albarghach NM; Metges JP; Pradier O; Visvikis D
J Nucl Med; 2010 Sep; 51(9):1368-76. PubMed ID: 20720054
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
30. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
[TBL] [Abstract][Full Text] [Related]
31. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
32. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
Yu J; Li X; Xing L; Mu D; Fu Z; Sun X; Sun X; Yang G; Zhang B; Sun X; Ling CC
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1468-74. PubMed ID: 19464822
[TBL] [Abstract][Full Text] [Related]
33. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
35. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
de Langen AJ; Klabbers B; Lubberink M; Boellaard R; Spreeuwenberg MD; Slotman BJ; de Bree R; Smit EF; Hoekstra OS; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):389-95. PubMed ID: 18931838
[TBL] [Abstract][Full Text] [Related]
36. Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora's box?
Devic S; Tomic N; Faria S; Menard S; Lisbona R; Lehnert S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1555-62. PubMed ID: 20646840
[TBL] [Abstract][Full Text] [Related]
37. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
[TBL] [Abstract][Full Text] [Related]
39. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
40. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]